The EPS miss and widening operating losses are negative signals for a pre-revenue biotech. However, the IBIO-600 Phase 1 start and $17M cash infusion provide near-term support. Watch for first participant dosing in Q2 2026 and any partnership news that could validate the pipeline.
Price Chart
Executive Summary
iBio reported Q3 FY2026 results with EPS of -$0.07 (GAAP) vs consensus -$0.06, a miss of ~16.7%. Revenue was $0, in line with expectations. The company highlighted regulatory clearance for IBIO-600 Phase 1 trial in Australia and preclinical data for IBIO-610, but operating losses widened to $8.4M from $4.9M a year ago. Cash runway extended into Q4 FY2028 via $17M warrant exercises, but the EPS miss and lack of revenue growth keep sentiment bearish.
Key Financial Metrics
Key Facts
- GAAP EPS -$0.07 vs consensus -$0.06 (miss of ~16.7%)
- Revenue $0 for Q3 FY2026, unchanged from prior year
- Operating loss widened to $8.4M from $4.9M YoY
- Cash and investments $74.8M as of March 31, 2026
- Received $17M from warrant exercises in Q4 FY2026, extending cash runway into Q4 FY2028
- Received regulatory clearance for IBIO-600 Phase 1 trial in Australia
- Preclinical data for IBIO-610 showed 6.7% visceral fat reduction in obese NHPs
- Expanded pipeline into PH-HFpEF with bispecific antibody program
Financial Impact
EPS miss of ~$0.01 vs consensus; operating loss increased by $3.5M YoY to $8.4M; cash runway extended by $17M warrant exercise
Risk Factors
- EPS miss of 16.7% vs consensus may pressure near-term sentiment
- Operating losses continue to widen with no near-term revenue catalyst
- Preclinical data for IBIO-610 is from a small, not statistically powered study
- Dilution risk from warrant exercises and potential future offerings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293395 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8210 | awaiting T+5 | — | $0.7181 (−12.53%) |
Oct 14, 2026 12d ago | SC 13G | $0.7808 $0.8400 | ▲ +7.58% | ▲ +7.13% | $0.7181 (−8.03%) |
Oct 13, 2026 14d ago | 8-K | $0.7818 $0.8210 | ▲ +5.01% | ▲ +6.17% | $0.7181 (−8.15%) |
Sep 14, 2026 6w ago | 8-K | $1.19 $1.33 | ▲ +11.76% | ▲ +9.64% | $0.7181 (−39.66%) |
Aug 28, 2026 8w ago | 8-K | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7181 (−47.20%) |
Aug 28, 2026 8w ago | Press Release | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7181 (−47.20%) |
Jul 1, 2026 16w ago | 8-K | $1.75 $1.59 | ▼ −9.14% | ▼ −9.40% | $0.7181 (−58.97%) |
May 15, 2026 23w ago | 3 | $1.47 $1.84 | ▲ +25.17% | ▲ +24.21% | $0.7181 (−51.15%) |
May 12, 2026 23w ago | Press Release | $1.55 $1.50 | ▲ +3.23% | ▲ +2.07% | $0.7181 (+53.67%) |
May 8, 2026 24w ago | 8-K | $1.66 $1.42 | ▼ −14.46% | ▼ −14.37% | $0.7181 (−56.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers